Tech Company Financing Transactions
PsiThera Funding Round
On 11/10/2026, PsiThera landed $25 million in funding from AbbVie Biotech Ventures, Lightstone Ventures and Samsara BioCapital.
Transaction Overview
Company Name
Announced On
11/10/2026
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds from the financing are expected to fund operations, supporting development candidate nomination and the initiation of IND-enabling studies for the company's lead oral small molecule TNFa inhibitor, as well as advancement of its oral TL1A program into lead optimization.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
66 Galen Street 202
Watertown, MA 02472
USA
Watertown, MA 02472
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
PsiThera is advancing programs across multiple targets from the tumor necrosis factor (TNF) superfamily and beyond, where no oral therapies currently exist. These could become the first oral treatments in their categories. Our pipeline targets represent major opportunities to bring biologic-like efficacy to patients--without injections.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Eric Shaff
Browse more venture capital transactions:
Prev: 11/10/2026: Scalestack venture capital transaction
Next: 11/10/2026: Efferon venture capital transaction
Share this article
About Database of VC Transactions
We report on every notable VC transaction. All VC database entries on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs